Company logo

KOD - Kodiak Sciences Inc.

NASDAQ -> Healthcare -> Biotechnology
Palo Alto, United States
Type: Equity

KOD price evolution
KOD
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Current assets
Cash $225.41 $252.1 $291.83
Short term investments
Net receivables
Inventory
Total current assets $202.49 $224.63 $251.51 $289.31
Long term investments
Property, plant & equipment $155.25 $161.91 $168.36 $175.02
Goodwill & intangible assets
Total noncurrent assets $176.95 $183.25 $190.06
Total investments
Total assets $372.67 $401.58 $434.76 $479.37
Current liabilities
Accounts payable $3.29 $1.87 $2.48 $13.61
Deferred revenue
Short long term debt $9.89 $9.61 $9.77
Total current liabilities $24.06 $21.2 $24.86 $41.73
Long term debt $65.87 $68.72 $71.86
Total noncurrent liabilities $165.87 $168.72 $171.86
Total debt $75.76 $78.32 $81.63
Total liabilities $187.3 $187.07 $193.57 $213.59
Shareholders' equity
Retained earnings -$1284.63 -$1240.69 -$1195.57 -$1152.53
Other shareholder equity
Total shareholder equity $214.51 $241.19 $265.78
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $291.83 $196.76 $737.83 $950.72
Short term investments $288.5 $24.58
Net receivables
Inventory
Total current assets $289.31 $486 $734.81 $972
Long term investments
Property, plant & equipment $175.02 $115.75 $108.07 $78.81
Goodwill & intangible assets
Total noncurrent assets $190.06 $180.62 $169.41 $95.34
Total investments $288.5 $24.58
Total assets $479.37 $666.63 $904.22 $1067.35
Current liabilities
Accounts payable $13.61 $9.13 $12.43 $8.65
Deferred revenue
Short long term debt $9.77 $9.93 $3.93 $2.37
Total current liabilities $41.73 $52.5 $64.68 $31.42
Long term debt $71.86 $77.81 $76.06 $75.03
Total noncurrent liabilities $171.86 $177.97 $176.22 $175.17
Total debt $81.63 $87.73 $80 $77.4
Total liabilities $213.59 $230.46 $240.9 $206.6
Shareholders' equity
Retained earnings -$1152.53 -$892.04 -$558.22 -$291.23
Other shareholder equity -$1.31 $0.05
Total shareholder equity $265.78 $436.17 $663.32 $860.75
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $32.51 $29.93 $46.63
Selling, general & administrative $15.47 $16.12 $16.75
Total operating expenses $46.63 $47.98 $46.05 $63.37
Operating income -$47.98 -$46.05 -$63.37
Income from continuing operations
EBIT -$45.12 -$43.04 -$59.52
Income tax expense
Interest expense $2.71
Net income
Net income -$43.95 -$45.12 -$43.04 -$59.52
Income (for common shares) -$45.12 -$43.04 -$59.52
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $206.3 $267.59 $217.34 $107.39
Selling, general & administrative $71.02 $73.79 $49.71 $28.62
Total operating expenses $277.32 $341.38 $267.05 $136.01
Operating income -$277.32 -$341.38 -$267.05 -$136.01
Income from continuing operations
EBIT -$260.48 -$333.81 -$266.97 -$133.07
Income tax expense
Interest expense $0.01 $0.02 $0.02 $0.03
Net income
Net income -$260.49 -$333.82 -$266.99 -$133.1
Income (for common shares) -$260.49 -$333.82 -$266.99 -$133.1
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Net income -$45.12 -$43.04 -$59.52
Operating activities
Depreciation $6.68 $6.65 $6.66
Business acquisitions & disposals
Stock-based compensation $18.38 $18.41 $22.83
Total cash flows from operations -$26.49 -$39.6 -$32.24
Investing activities
Capital expenditures -$0.05 -$0.02 -$27.48
Investments -$0.21 -$0.14
Total cash flows from investing -$0.63 -$0.26 -$0.17 -$27.8
Financing activities
Dividends paid
Sale and purchase of stock $0.06 $0.04 $0.05
Net borrowings
Total cash flows from financing $0.1 $0.06 $0.04 -$0.12
Effect of exchange rate
Change in cash and equivalents -$87.78 -$26.69 -$39.73 -$60.16
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$260.49 -$333.82 -$266.99 -$133.1
Operating activities
Depreciation $25.95 $11 $8.71 $4.21
Business acquisitions & disposals
Stock-based compensation $88.56 $106.03 $61.38 $30.67
Total cash flows from operations -$154.18 -$206.46 -$182.27 -$83.43
Investing activities
Capital expenditures -$41.43 -$47.36 -$63.3 -$7
Investments $290.65 -$289.77 $24.5 $111.83
Total cash flows from investing $249.23 -$336.51 -$38.8 $104.83
Financing activities
Dividends paid
Sale and purchase of stock $0.24 $1.94 $8.23 $617.78
Net borrowings -$0.01
Total cash flows from financing $0.03 $1.9 $8.18 $717.38
Effect of exchange rate
Change in cash and equivalents $95.07 -$541.08 -$212.89 $738.78
Fundamentals
Market cap $336.79M
Enterprise value N/A
Shares outstanding 52.62M
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income -$191.62M
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio -1.76
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS -$3.64
ROA -45.40%
ROE N/A
Debt/Equity 0.80
Net debt/EBITDA N/A
Current ratio 8.42
Quick ratio N/A